Form 4: Mirum Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
Christopher Peetz, CHIEF EXECUTIVE OFFICER and a Director of Mirum Pharmaceuticals, Inc., sold 30,000 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 30,000 Common Stock at $2.94 ($88,080) on September 1, 2026; holds 224,440 after (Direct).
- Open-market sale: disposed of 8,312 Common Stock at $98.08 ($815,241) on September 1, 2026; holds 216,128 after (Direct).
- Open-market sale: disposed of 21,688 Common Stock at $98.91 ($2,145,160) on September 1, 2026; holds 194,440 after (Direct).
- Option exercise/conversion: disposed of 30,000 Employee Stock Option (right to buy) on September 1, 2026; holds 58,487 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,960,401 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Peetz — Director, Officer (CHIEF EXECUTIVE OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 30,000 | $3 | $88.1K | 224,440 |
| 2026-09-01 | Open-market sale | Common Stock | 8,312 | $98 | $815.2K | 216,128 |
| 2026-09-01 | Open-market sale | Common Stock | 21,688 | $99 | $2.1M | 194,440 |
| 2026-09-01 | Option exercise/conversion | Employee Stock Option (right to buy) | 30,000 | — | — | 58,487 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (30,000 shares) |
| 2026-09-01 | Open-market sale (8,312 shares) |
| 2026-09-01 | Open-market sale (21,688 shares) |
| 2026-09-01 | Option exercise/conversion (30,000 shares) |
Keywords
insider transaction, Form 4, MIRM, Mirum Pharmaceuticals, Inc., bearish, Christopher Peetz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.